Mirikizumab usage and dosage

Mirikizumab-Omvoh is a biologic indicated for the treatment of moderately to severely active ulcerative colitis in adults. Before using militizumab, doctors need to conduct a thorough evaluation of the patient to ensure they are suitable for the treatment.

First, patients must be evaluated for tuberculosis (TB) infection before starting militizumab. This is because militizumab, as an immunosuppressant, may increase the risk of infection. Doctors also need to obtain the patient's liver enzyme and bilirubin levels to monitor for potential liver function abnormalities. In addition, ensuring patients have completed all age-appropriate vaccinations according to current immunization guidelines is a necessary step to help reduce the risk of infection.

The recommended dose of militizumab is divided into induction dose and maintenance dose. The induction dose is 300mg, and the specific administration time is week 0, week 4, and week 8. It is intravenous infusion, and the entire infusion process takes at least 30 minutes. This method of administration is designed to rapidly increase drug concentrations in the body in order to effectively control disease activity. This is followed by a maintenance phase, with the recommended maintenance dose of 200 mg administered by subcutaneous injection at week 12. During maintenance treatment, the injection needs to be divided into two consecutive injections, each of 100 mg, and then injected every four weeks to ensure that the blood drug concentration remains within the effective range.

Regarding medication management, militizumab is mainly administered by intravenous injection and is administered by professional doctors using aseptic techniques. Each vial of militizumab is for single use only, which means patients should use a new vial with each treatment. At the same time, a complete maintenance dose requires2 prefilled pens or 2 prefilled syringes to ensure dosing accuracy. When giving subcutaneous injections, recommended injection sites include the abdomen, thighs, and back of the upper arms. To reduce local tissue damage, patients should receive injections at different locations. For example, if the first injection is in the abdomen, it is recommended that the second injection be given in another area of u200bu200bthe abdomen, in the upper arm, or thigh. It is also important that injections should not be given in areas of tender skin, bruises, erythema, or induration to avoid discomfort or complications.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472cbe04-263e-433d-9a0f-58c1b50b715a##